A drug that can halve the risk of developing breast cancer in post-menopausal women has been approved for use in the UK. This drug, called anastrozole, could benefit an estimated 289,000 women in the UK who are at increased ...
Nov 9, 2023
0
0
A new drug to treat postpartum depression will cost nearly $16,000 for a 14-day course of treatment, a price tag that has doctors worried that some patients won't be able to afford the medication.
Nov 8, 2023
0
11
According to new research at ACR Convergence 2023, the American College of Rheumatology's (ACR) annual meeting, continuing tumor necrosis factor inhibitors during pregnancy is not associated with worse fetal or obstetric ...
Nov 7, 2023
0
1
In a recent study published in Leukemia, Finnish researchers investigated why some patients with chronic myeloid leukemia (CML) can discontinue their daily medication safely.
Nov 6, 2023
0
0
Researchers have identified genetic tests that predict which cancer patients may benefit from the drugs in combination with chemotherapy.
Nov 6, 2023
0
0
Ripretinib is a tyrosine kinase inhibitor that was approved by the United States FDA in 2020 for treatment of advanced gastrointestinal stromal tumor (GIST) in patients who received prior treatment with three or more tyrosine ...
Nov 6, 2023
0
0
A new editorial paper titled "The uncharted role of HER2 mutant alleles in breast cancer has been published in Oncotarget.
Nov 6, 2023
0
1
Sodium-glucose cotransporter-2 (SGLT2) inhibitors lower blood sugar levels and have additional beneficial effects on kidney and heart health for individuals with and without diabetes, but little is known about the safety ...
Nov 4, 2023
0
1
Sodium-glucose cotransporter-2 (SGLT2) inhibitors, which are medications that lower blood sugar levels among other effects, provide kidney- and heart-related benefits to patients with and without diabetes. An exploratory ...
Nov 3, 2023
0
4
Teenagers are more likely to visit their GP about depression and anxiety at the start of the school year in the autumn, according to new research led by experts from the University of Nottingham.
Nov 2, 2023
0
0
